CF PharmTech, Inc. (02652) completed a share repurchase on 11 February 2026, reducing the number of issued shares (excluding treasury shares) from 301,999,586 to 301,985,586. Treasury shares increased from 224,000 to 238,000, bringing the total number of issued shares to 302,223,586.

On the same date, 14,000 shares were repurchased on the market at a highest price of HKD 35.6 and a lowest price of HKD 35.08, for a total consideration of HKD 492,700. These repurchased shares were designated for holding as treasury shares, and the activity was carried out under a repurchase mandate approved on 16 December 2025. According to the filing, 238,000 shares have been repurchased in total under the current mandate, representing 0.0787% of the issued shares (excluding treasury shares) as of the mandate date.

The disclosure also indicates a moratorium period up to 13 March 2026 regarding any new share issuance or transfers of treasury shares, in accordance with applicable listing rules and regulations.